David Moore

Jan 9, 2025 | nature.com | Dhruva Biswas |Yun-Hsin Liu |Javier Herrero |Yin Chao Wu |David Moore |Takahiro Karasaki | +18 more

AbstractHuman tumors are diverse in their natural history and response to treatment, which in part results from genetic and transcriptomic heterogeneity. In clinical practice, single-site needle biopsies are used to sample this diversity, but cancer biomarkers may be confounded by spatiogenomic heterogeneity within individual tumors.

Nov 6, 2024 | nature.com | Oriol Pich |Kerstin Thol |Jens Luebeck |Natasha E. Weiser |Wei-Ting Lu |Brooke E. Howitt | +11 more

AbstractExtrachromosomal DNA (ecDNA) is a major contributor to treatment resistance and poor outcome for patients with cancer1,2. Here we examine the diversity of ecDNA elements across cancer, revealing the associated tissue, genetic and mutational contexts. By analysing data from 14,778 patients with 39 tumour types from the 100,000 Genomes Project, we demonstrate that 17.1% of tumour samples contain ecDNA.

Sep 18, 2024 | thermofisher.com | David Moore |George Stez

Since even neutral carbohydrates can be readily ionized in high pH conditions, ion chromatography (IC) has become an indispensable analytical tool in the food and beverage (F&B) and biopharmaceutical industries. In F&B, IC helps manufacturers precisely measure sugars, sugar alcohols, and other carbohydrates in products ranging from soft drinks to functional foods. This capability is crucial for nutritional labeling, quality control, and developing new formulations.

Jul 4, 2024 | nature.com | Alexander Frankell |Michelle Dietzen |Maise Al Bakir |Takahiro Karasaki |Sophia Ward |Emma Colliver | +25 more

Correction to: Nature https://doi.org/10.1038/s41586-023-05783-5 Published online 12 April 2023In the version of the article initially published, the symbols for death (x) and censored (>) were swapped in the graphs in Fig. 1. The figure has now been corrected in the HTML and PDF versions of the article.

May 31, 2024 | nature.com | Robert Hynds |Ariana Huebner |David Pearce |Mark Hill |Ayse U. Akarca |David Moore | +17 more

AbstractPatient-derived xenograft (PDX) models are widely used in cancer research. To investigate the genomic fidelity of non-small cell lung cancer PDX models, we established 48 PDX models from 22 patients enrolled in the TRACERx study. Multi-region tumor sampling increased successful PDX engraftment and most models were histologically similar to their parent tumor.